These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11778971)

  • 1. Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate.
    Behe M; Du J; Becker W; Behr T; Angerstein C; Márquez M; Hiltunen J; Nilsson S; Holmberg AR
    Med Oncol; 2001; 18(1):59-64. PubMed ID: 11778971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes.
    Wulbrand U; Feldman M; Pfestroff A; Fehman HC; Du J; Hiltunen J; Marquez M; Arnold R; Westlin JE; Nilsson S; Holmberg AR
    Cancer; 2002 Feb; 94(4 Suppl):1293-7. PubMed ID: 11877759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism.
    Viguerie N; Tahiri-Jouti N; Ayral AM; Cambillau C; Scemama JL; Bastié MJ; Knuhtsen S; Estève JP; Pradayrol L; Susini C
    Endocrinology; 1989 Feb; 124(2):1017-25. PubMed ID: 2563240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
    Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
    Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity in hepatic transport of somatostatin analog octapeptides.
    Fricker G; Dubost V; Schwab D; Bruns C; Thiele C
    Hepatology; 1994 Jul; 20(1 Pt 1):191-200. PubMed ID: 8020889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET).
    Mäcke HR; Smith-Jones P; Maina T; Stolz B; Albert R; Bruns C; Reist H
    Horm Metab Res Suppl; 1993; 27():12-7. PubMed ID: 8392486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats.
    Breeman WA; de Jong M; Bernard B; Hofland LJ; Srinivasan A; van der Pluijm M; Bakker WH; Visser TJ; Krenning EP
    Anticancer Res; 1998; 18(1A):83-9. PubMed ID: 9568060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.
    Schottelius M; Rau F; Reubi JC; Schwaiger M; Wester HJ
    Bioconjug Chem; 2005; 16(2):429-37. PubMed ID: 15769098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.
    Weckbecker G; Briner U; Lewis I; Bruns C
    Endocrinology; 2002 Oct; 143(10):4123-30. PubMed ID: 12239124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
    Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ
    J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
    Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
    J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
    de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
    Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of SMS 201-995 in healthy subjects.
    Kutz K; Nüesch E; Rosenthaler J
    Scand J Gastroenterol Suppl; 1986; 119():65-72. PubMed ID: 2876508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer.
    Joensuu TK; Nilsson S; Holmberg AR; Márquez M; Tenhunen M; Saarto T; Joensuu H
    Ann N Y Acad Sci; 2004 Dec; 1028():361-74. PubMed ID: 15650261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy.
    De K; Bhowmik A; Behera A; Banerjee I; Ghosh MK; Misra M
    J Pept Sci; 2012 Dec; 18(12):720-30. PubMed ID: 23109400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.